Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine.

ABSTRACT:

Objective

The primary objective was to characterize the pharmacokinetics (PK) and safety of eptinezumab in children and adolescents with migraine.

Background

Migraine in children and adolescents is a prevalent and potentially debilitating disease, and few preventive therapies are approved for use in these populations. Eptinezumab, a calcitonin gene-related peptide monoclonal antibody approved for migraine prevention in adults, has demonstrated efficacy at doses of 100 mg or 300 mg administered intravenously every 12 weeks. Defining the appropriate dosing of eptinezumab in children and adolescents is required to accurately examine the safety and efficacy of its use as a preventive migraine therapy.

Methods

In this open-label PK clinical trial conducted between August 2

SUBMITTER: Hershey AD 

PROVIDER: S-EPMC12497927 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature